机构:[1]Department of Nuclear Medicine, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, People's Republic of China四川省人民医院四川省肿瘤医院
Recently, radionuclide labelling fibroblast activating protein inhibitors (FAPI) is regarded as the most promising imaging tracer forvarious tumours. Here we present the imaging finding of aluminium-[18F] fluoride (Al18F)-labelled 1,4,7-triazacyclononane-N,N',N"-triacetic acid (Al18F-NOTA-FAPI-04) and fluorine-18-fluorodeoxyglucose (18F-FDG) in postoperative recurrence esophageal cancer. The results presented that imaging with Al18F-NOTA-FAPI-04 showed significant improvement in detection of local recurrence and distant metastasis with higher maximum standardized uptake value (SUVmax) in the lesions compared with 18F-FDG.
第一作者机构:[1]Department of Nuclear Medicine, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, People's Republic of China
共同第一作者:
通讯作者:
通讯机构:[1]Department of Nuclear Medicine, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, People's Republic of China[*1]Department of Nuclear Medicine, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, People's Republic of China
推荐引用方式(GB/T 7714):
Zhang Wei,Diao Wei,Cheng Zhuzhong.Comparison of Al 18F-NOTA-FAPI-04 and 18F-FDG in recurrent esophageal cancer after surgery[J].HELLENIC JOURNAL OF NUCLEAR MEDICINE.2023,26(1):75-77.doi:10.1967/s002449912559.
APA:
Zhang Wei,Diao Wei&Cheng Zhuzhong.(2023).Comparison of Al 18F-NOTA-FAPI-04 and 18F-FDG in recurrent esophageal cancer after surgery.HELLENIC JOURNAL OF NUCLEAR MEDICINE,26,(1)
MLA:
Zhang Wei,et al."Comparison of Al 18F-NOTA-FAPI-04 and 18F-FDG in recurrent esophageal cancer after surgery".HELLENIC JOURNAL OF NUCLEAR MEDICINE 26..1(2023):75-77